Allianz Asset Management GmbH Sells 15,301 Shares of Cabot Corporation $CBT

Allianz Asset Management GmbH reduced its stake in shares of Cabot Corporation (NYSE:CBT) by 24.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 47,894 shares of the specialty chemicals company’s stock after selling 15,301 shares during the quarter. Allianz Asset Management GmbH owned about 0.09% of Cabot worth $3,642,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. NewEdge Advisors LLC grew its holdings in Cabot by 2,559.5% during the first quarter. NewEdge Advisors LLC now owns 984 shares of the specialty chemicals company’s stock valued at $82,000 after purchasing an additional 947 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Cabot by 32.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 442,646 shares of the specialty chemicals company’s stock valued at $36,802,000 after buying an additional 108,645 shares during the period. Empowered Funds LLC increased its position in shares of Cabot by 102.6% in the 1st quarter. Empowered Funds LLC now owns 28,162 shares of the specialty chemicals company’s stock valued at $2,341,000 after buying an additional 14,260 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Cabot by 3.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 122,022 shares of the specialty chemicals company’s stock worth $10,145,000 after buying an additional 4,048 shares during the period. Finally, Geneos Wealth Management Inc. lifted its holdings in Cabot by 409.0% during the first quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company’s stock worth $38,000 after acquiring an additional 364 shares in the last quarter. 93.18% of the stock is currently owned by institutional investors and hedge funds.

Cabot Price Performance

NYSE:CBT opened at $75.73 on Wednesday. The company has a market cap of $3.95 billion, a P/E ratio of 13.26, a P/E/G ratio of 3.91 and a beta of 0.88. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.67 and a quick ratio of 1.09. Cabot Corporation has a one year low of $58.33 and a one year high of $89.15. The firm’s fifty day moving average price is $69.74 and its two-hundred day moving average price is $71.60.

Cabot (NYSE:CBT) last posted its earnings results on Tuesday, February 3rd. The specialty chemicals company reported $1.53 EPS for the quarter, beating the consensus estimate of $1.40 by $0.13. The company had revenue of $849.00 million for the quarter, compared to the consensus estimate of $889.11 million. Cabot had a return on equity of 22.82% and a net margin of 8.62%.The firm’s revenue for the quarter was down 11.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.76 earnings per share. Cabot has set its FY 2026 guidance at 6.000-6.500 EPS. Equities analysts expect that Cabot Corporation will post 7.57 earnings per share for the current year.

Cabot Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 13th. Stockholders of record on Friday, February 27th will be issued a dividend of $0.45 per share. The ex-dividend date of this dividend is Friday, February 27th. This represents a $1.80 annualized dividend and a dividend yield of 2.4%. Cabot’s dividend payout ratio (DPR) is currently 31.52%.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. JPMorgan Chase & Co. lowered their price target on Cabot from $75.00 to $54.00 and set an “underweight” rating for the company in a report on Friday, November 28th. Jefferies Financial Group reissued a “buy” rating and set a $85.00 target price on shares of Cabot in a research note on Wednesday, February 4th. Mizuho set a $75.00 price target on shares of Cabot and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Weiss Ratings reissued a “hold (c-)” rating on shares of Cabot in a research report on Monday, December 29th. Finally, UBS Group boosted their price objective on shares of Cabot from $74.00 to $81.00 and gave the company a “neutral” rating in a research report on Thursday, February 5th. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Cabot presently has an average rating of “Hold” and an average target price of $73.75.

About Cabot

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.